What Are Common Reasons for Document Deficiencies in Overseas Registration of POCT Products?

During overseas registration of POCT products, document deficiencies are the most common review outcome. Manufacturers often receive deficiency notices due to incorrect product classification, incomplete technical documentation, performance validation not meeting target market requirements, insufficient clinical evidence, non-localized labeling and instructions, quality management system non-compliance with local regulations, failure to appoint a valid authorized representative, or absence of a post-market surveillance plan. The core issue is that companies fail to first verify whether the product falls under the target country's medical device regulatory scope, do not select the registration pathway based on risk classification, and do not assess the reusability of existing NMPA, CE, or FDA documentation.

Key Actions to Avoid Deficiencies

Accurate Classification and Registration Pathway

Precisely determine the product's classification and registration pathway in each target country. Confirm whether the product is a medical device, drug, combination product, or general health product. Assess risk level—self-testing, infectious disease, and critical value tests are typically higher risk and require stricter clinical evidence. Decide on the appropriate registration pathway (e.g., US CLIA classification, EU IVDR class A/B/C/D, China IVD classification).

Complete Technical Documentation

Ensure technical documents such as performance specifications, risk management, and stability data meet target country standards. Include analytical performance evaluation (precision, accuracy, linearity, interference, cross-reactivity), stability studies (real-time, accelerated, transport simulation), reference interval studies based on local populations, and clinical evaluation or trial reports.

Localized Labeling and Instructions

Provide labeling and instructions for use in the local language, including required warnings, symbols, and units of measurement. Ensure consistency with the product's intended use and target market regulations.

Appoint a Qualified Local Agent or Authorized Representative

Appoint a local agent or authorized representative with clear responsibilities covering registration, post-market changes, renewal, and adverse event reporting. Ensure the representative's qualifications and contractual control over certificates.

Post-Market Surveillance Plan

Establish a post-market surveillance and adverse event reporting system, including PMS reports, periodic safety updates, product tracking, and recall plans.

Common Reasons for Deficiencies

• Product classification error: Submitting a Class II device as Class I, or misclassifying an IVD as a drug.
• Incomplete performance validation: Not covering all applicable sample types (whole blood, serum, plasma) or insufficient sample size for statistical requirements.
• Inadequate reference interval study: Not stratifying by age, gender, or region, or failing to exclude potential disease populations.
• Clinical evaluation mismatch: e.g., claiming self-testing use but conducting clinical studies in professional healthcare settings without user verification.
• Non-localized labeling: Only translating the title, ignoring local regulatory requirements for warnings, symbols, and language usage (e.g., Spanish, Arabic).
• Expired or out-of-scope QMS certificate: ISO 13485 certificate expired or not covering the POCT product, or missing MDSAP certification (e.g., for Brazil, Japan, Canada).
• Invalid authorized representative: Agreement does not cover post-registration changes, renewal, or adverse event reporting, or the representative lacks qualifications.
• Missing post-market surveillance plan: No adverse event monitoring procedure, product tracking records, or recall plan.

Preparation Checklist

1. Confirm product regulatory classification and registration pathway for each target country.
2. Compile technical file templates including product description, design history, manufacturing process, performance specifications, and stability data.
3. Prepare analytical performance validation reports with data from representative target population samples.
4. Prepare clinical evaluation reports based on literature, clinical trials, or both, with clear evaluation criteria.
5. Prepare risk management documents per ISO 14971 or equivalent standard, identifying all risks and control measures.
6. Design labeling and instructions in compliance with local regulations and language.
7. Review QMS certificates to ensure validity and product coverage; apply for MDSAP if needed.
8. Engage an authorized representative or local agent with a clear agreement outlining responsibilities.
9. Develop a post-market surveillance plan including PMS reports, adverse event reporting, and periodic updates.
10. Conduct an internal pre-audit against target country registration guidelines.

AIMEILI Regulatory Interpretation and Business Impact

Manufacturers often mistakenly assume that POCT products are simple and have low registration barriers, leading them to neglect clinical evidence and localization requirements. In reality, due to the complex use environment (non-laboratory settings, varying operator skills), regulators impose higher standards for stability and usability. The first two priorities in a project should be: (1) accurately determine the product classification and registration pathway in each target country, and (2) identify gaps between existing technical files and target country requirements, especially reference intervals, clinical evaluation, and labeling.

ISO 13485 certificates and CE technical files are the most reusable assets, but risk management reports, software validation documents, and stability data often need adjustment based on target market characteristics (e.g., high temperature and humidity storage for tropical countries). Choosing the right local agent or authorized representative is critical—they not only bear legal obligations but also handle deficiency communications and certificate maintenance. Select institutions with medical device registration experience and a good reputation, and retain control over certificates.

For multi-country registrations, adopt a 'core file + country-specific differences' approach to turn deficiency experiences into standardized processes, significantly reducing repetitive work and deficiency risks. Remember: deficiencies are not the end but a normal part of the registration process; establishing a rapid response mechanism and a template library can markedly shorten approval timelines.

Based on AIMEILI registration practice database, medical device international registration knowledge base, and publicly available regulatory information. Specific projects should be guided by the latest requirements of the target country's regulatory authority and product documentation.